Migraine

Anti-CGRP monoclonal antibodies for migraine prevention were not linked to increased cardiovascular risk, per a Medicare study, addressing earlier safety concerns.

Participants with greater vitamin D levels had a 16% lower migraine prevalence than those with lower vitamin D levels.

We spotlight 5 impactful regulatory decisions scheduled to occur during the first quarter of 2025.

Atogepant 60 mg, an oral CGRP receptor antagonist, demonstrated rapid and effective migraine prevention, reducing frequency and improving function in 4 weeks.

In a recent study, the prevalence of RLS occurred in 42.9% of participants with depression.

A recent study examined the phase 3 trials ADVANCE, PROGRESS, and ELEVATE and saw atogepant 60 mg as a preventive migraine treatment improves quality of life and functioning.

A new study found that individuals with healthier cardiovascular systems are more likely to develop migraines, linking incident migraine to lower cardiovascular risk.

A new study found that the more military personnel are exposed to open burn pits over time, the greater their odds will be for developing headache disorders or migraine.

A study found that migraine-related disability worsens health-related quality of life, with gender-specific differences, particularly affecting women with mild disability.

Phase 3 data found 66.5% of people with migraine attacks treated with STS101 had headache pain relief two hours after the dose.

A meta-analysis revealed taking pregabalin with supplement vitamin D reduced migraine frequency in children by 88%

A study finds CGRP monoclonal antibodies are not clinically superior to topiramate or Botox in treating chronic migraines, raising cost-effectiveness concerns.

Comorbid migraine and insomnia are linked to altered locus coeruleus connectivity, suggesting it is a biomarker for sleep disturbances and a potential therapeutic target.

A meta-analysis shows that wet cupping reduces migraine intensity but doesn't improve quality of life. Adjunctive therapies offer limited additional benefits.

A study of > 14,000 patients offers insights on real-world usage and characteristics of new rimegepant users, showing distinct patterns in acute vs. preventive treatment.

Triptans, including eletriptan and sumatriptan, offer better migraine relief than newer, more expensive drugs, suggesting they should be first-line treatments.

A study revealed erenumab at 140 mg is effective and safe in achieving remission of headaches caused by non-opioid medication overuse.

Taking ubrogepant at the first signs of a migraine, before headache onset, significantly reduces migraine symptoms and improves daily function, a study in Neurology reveals.

Investigators found patients with comorbid temporomandibular disorder, migraines, and fibromyalgia experienced longer pain duration than patients with only 1 comorbidity.

New research found high diastolic blood pressure is linked to greater odds of a female having a migraine. The study found no other associations between migraines and other CVD factors.

Data from a phase 2 randomized clinical trial demonstrate use of the GLP-1 receptor agonist exenatide could be used as a treatment for idiopathic intracranial hypertension in women.

Forget what you think you know about red wine or chocolate ‘activating’ migraine. Many commonly accepted “triggers” aren’t triggers at all.

Trigger avoidance-only strategies don’t actually help migraine patients improve. These are the proactive behaviors that do.

It’s time to stop just recommending trigger avoidance strategies to patients. These are the proactive behaviors that will actually help improve migraine.

There was no association found between migraines and Crohn’s disease or ulcerative colitis.

AXS-07 showed statistical significance for migraine pain freedom at 90 minutes, and at every time point after.

The oral CGRP antagonist becomes the first in its class approved for the indication.

The oral therapy showed benefit in reducing symptoms and migraine-related pain, as well as aura, within 2 hours of administration.

Drinking more than 3 servings of caffeinated beverages per day was associated with an increase in migraine headaches.

Rimegepant (rimegepant Zydis), which is a novel therapy for treatment of acute migraines, was found to reduce bothersome suymptoms and eliminate pain in a phase 3 clinical trial.